WASHINGTON--(BUSINESS WIRE)--Today, the Biotechnology Industry Organization (BIO) released a first-of-its-kind study on venture financing broken down by disease area and novelty of research over a ten-year period from 2004 to 2013.
“Since venture financing is the lifeblood of our industry, we wanted to better understand trends in venture financing over the last decade by conducting the broadest, most comprehensive study possible,” said Cartier Esham, PhD, Executive Vice President of Emerging Companies. “The aim was to identify funding trends for emerging drug developers within specific therapeutic areas and across varying levels of innovation.”
The report analyzes data from four venture capital databases – Thomson Reuters, BioCentury, Elsevier, and Evaluate Pharm – to investigate investor trends, examine investment in specific therapeutic areas and indications, and identify disease areas that might be struggling for early-stage venture equity financing. The study encompasses $38 billion of venture capital into more than 1,200 U.S. drug companies, receiving more than 2,000 rounds of funding over the last 10 years from 2004-2013.
Key findings include:
- Seventy-eight percent of U.S. venture investment for therapeutics went toward novel drug R&D, suggesting innovation is a core priority for venture investors
- Total venture funding of drug R&D dropped 21 percent, from $21.5 billion to $16.7 billion, comparing five-year periods before and after the recent financial crisis (2004-2008 vs. 2009-2013)
- Disease areas affecting large populations – Diabetes, Psychiatry, Gastrointestinal, Respiratory, Cardiovascular – have seen a decline in novel drug R&D venture funding
- Rare disease funding has seen a large increase over the past decade in terms of both dollars raised and number of companies funded
- There are fewer first-time Series A financings in recent years, down 30 percent from a peak in 2006, but higher dollar amounts for novel drug R&D venture funding
The BIO Industry Analysis team will release study findings at the 2015 BIO CEO & Investor Conference, taking place February 9-10 in New York City. Conference attendees will have early access to the full report, including presentation of the data and a panel discussion with seasoned venture capitalists.
BIO CEO & Investor Conference media registration is complimentary for credentialed members of the media. All registrations are subject to verification of credentials.
The latest content from BIO Industry Analysis can be found at http://biotech-now.org.
For more information on BIO and the biotechnology industry, please visit http://www.bio.org.
About BIO
BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO's blog chronicling “innovations transforming our world” and the BIO Newsletter is the organization’s bi-weekly email newsletter. Subscribe to the BIO Newsletter.
Upcoming BIO Events
BIO
CEO & Investor Conference
February 9-10, 2015
New York
City, NY
BIO-Europe
Spring
March 9-11, 2015
Paris, France
BIO
Asia International Conference
March 24-25, 2015
Tokyo,
Japan
BioEquity
Europe
May 19-20, 2015
Vienna, Austria
BIO
International Convention
June 15-18, 2015
Philadelphia, PA
